Future investigations could utilize advanced technologies, such as gene editing and proteomics, to conduct an in-depth analysis of the transcriptional and post-transcriptional regulatory networks associated with MTA3 in NSCLC. This evidence concerns the gene MTA3 and non-small cell lung carcinoma.